Health Care • Medical/Dental Instruments
$55.48 ▲ +1.81
(+3.37%)
MKT CAP: $3.96B • VOL: 344.7K
52W L $13 52W H $59
ROARABLE / RQD
D- • 41/100
PIOTROSKI
2 / 9
PLSE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $350.0K | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | -$189.0K | — | — |
| Gross Margin % | -50.0% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$76.9M | -$56.3M | -$43.6M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$72.8M | -$53.6M | -$42.2M |
| EBITDA (Normalized) | -$76.7M | -$56.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$54.1M | -$36.3M | -$33.0M |
| Capital Expenditures (CapEx) | $315.0K | $125.0K | — |
| Free Cash Flow (FCF) | -$54.4M | -$36.5M | -$33.0M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $80.7M | $118.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $80.7M | $114.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PLSE.